Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

J&J Pops on Decision to Split Consumer Health Business

Published 12/11/2021, 13:42
Updated 12/11/2021, 13:42
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:JNJ) stock jumped more than 5% in Friday’s trading as the company revealed its plan to split its consumer health business into a separate listed entity.

The separation is expected to take 18 to 24 months to complete, J&J said in a release.

The consumer health segment that houses brands such as Neutrogena, Band-Aid, Listerine and Tylenol, is expected to generate revenue of approximately $15 billion in the ongoing financial year. That compares with the roughly $77 billion generated by the pharmaceutical and medical device unit, which also sells the Covid-19 vaccine. 

J&J’s Covid vaccine is one of the only three allowed to be sold in the U.S. The other two belong to Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), respectively.

J&J is the third big company in less than a week to have announced separation of their businesses, General Electric (NYSE:GE) and Toshiba (T:6502) before it. It also echoes a similar process also underway at the U.K.'s GlaxoSmithKline (NYSE:GSK).  Conglomerates have tended to traded at discounts to specialist companies in the past, and J&J's current price-earnings multiple of 24 compares poorly to - for example - Eli Lilly (NYSE:LLY) stock, which trades at over 40 times earnings.

As per a reorganization announced on Friday, Alex Gorsky will serve as Executive Chairman of J&J and pass the Chief Executive Officer's role to Joaquin Duato.

According to The Wall Street Journal, J&J has planned the restructuring so as to be tax-free. It is likely J&J would spin out its consumer unit and hold a stock offering, but no decision has been made, Gorsky told the Journal.

 

 

 

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.